Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assess Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Admnd at 3 & 4 Mths & DTPa-HBV-IPV/Hib Vaccine Admnd at 5 Mths, Followed by DTPa-IPV/Hib Vaccine at 18 Mths in Infants Who Received hepatitisB Vaccine at Birth & at One Month of Age

NCT00325143 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00325143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00325143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assess Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Admnd at 3 & 4 Mths & DTPa-HBV-IPV/Hib Vaccine Admnd at 5 Mths, Followed by DTPa-IPV/Hib Vaccine at 18 Mths in Infants Who Received hepatitisB Vaccine at Birth & at One Month of Age
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
December 1, 2003
Completion date
February 1, 2007
Enrollment
702 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, haemophilus influenzae type b, poliomyelitis, tetanus